The goal of outpatient treatment of COVID-19 is to prevent hospitalizations. However, it is often difficult to know who to treat. This activity provides an expert’s commentary on rethinking how we are approaching treatment of ambulatory patients with COVID-19 infections.
After completing this activity, participants should be better able to:
- Describe current and novel strategies for testing and prevention of COVID-19
- Apply the latest recommended management strategies to the treatment of patients with COVID-19
- Identify patients who are eligible for monoclonal antibody treatment for COVID-19
NPs and PAs
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Mary Knudtson, DNSc, NP, FAAN, University of California, Irvine, Irvine, California
Nursing contact hours: 0.25 which includes 0.25 hours of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until March 31, 2023. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Daniel Forsberg, PA-C, MPH, CPH, Touro College, Skokie, Illinois
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credits for learning and change.
This activity is supported by an educational grant from Gilead Sciences, Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Anderson (staff): previous stock ownership: Merck.
Dr Ison: consulting fees: Adagio, ADMA Biologics, AlloVir; consulting fees/fees for non-CME/CE services: Genentech; contracted research: GlaxoSmithKline, Pulmocide.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose, except Dr Anderson as noted above.
Participants wishing to earn CE/CME credit must:
- Review the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
The estimated time to complete this activity is 0.25 hours.
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 100%.
Release date: April 1, 2022
Expiration date: March 31, 2023
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 102321C-CCT3